Login to Your Account



In The Clinic NEWS

Shares of San Diego-based Vical Inc. fell 23 percent, or 43 cents, to $1.44 Monday as longtime partner Astellas Pharma Inc. took the wraps off top-line data showing that ASP-0113 failed to meet primary or secondary endpoints of the phase III study.

Onconova Therapeutics Inc. CEO Ramesh Kumar noted that "the more direct RAS target approaches have so far not succeeded, although a lot of work is going on," and that's why his firm chose a different route with rigosertib in myelodysplastic syndromes (MDS).

Wedbush Securities analyst Liana Moussatos called top-line results from two trials by Kala Pharmaceuticals Inc. "the best phase III dry eye data that I've seen," though not everyone seemed as enthusiastic about the outcomes with KPI-121 0.25 percent vs. placebo.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: